Cipla Ltd · NSE:CIPLA
Cipla — Q4 FY2014 Earnings Presentation
12 slides from Cipla's earnings presentation, May 29, 2014
Slide 1: Investor Presentation Q4 FY14 Earnings Release
Corporate CorporatePresentation Presentation Investor Presentation Q4 FY 14 Earnings Release 29 May 2014 Investor Presentation 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Financial Performance Summary – Q4 2013-14
Financial Performance Summary – Q4 2013-14 Quarterly Numbers Standalone Consolidated Actuals Actuals vs Q4 FY 13 vs Q3 FY 14 vs Q4 FY 13 vs Q3 FY 14 (Rs Cr.) (Rs Cr.) Revenue 2,287 16.7% 0.3% 2,520 27.3% -2.4% EBITDA 358 -12.5% -11.1% 409 -3.9% -12.4% EBITDA % 15.7% -5.2% -2.0% 16.2% -5.3% -1.9% PAT
Slide 4: Financial Performance Summary – FY 2013-14
Financial Performance Summary – FY 2013-14 Full Year Numbers Standalone Consolidated Actuals Actuals vs FY 13 vs FY 13 (Rs Cr.) (Rs Cr.) Revenue 9,380 14.4% 10,100 22.0% EBITDA 1,990 -6.1% 2,133 -2.9% EBITDA % 21.2% -4.6% 21.1% -5.4% PAT 1,388 -7.9% 1,388 -10.1% PAT % 14.8% -3.6% 13.7% -4.9% R&D 518
Slide 5: Summary of Performance
Summary of Performance Area Achievements ▪ Ending year 1 of a 2 year investment cycle ▪ Robust sales growth (22% vs. previous year); crossed Rs. 10,000 crore mark ▪ Strong operating cash flow >60% of operating profit for the year Financial Performance ▪ EBITDA on track based on agreed 3 year plan wi
Slide 6: Summary of Performance
Summary of Performance Area Achievements ▪ R&D expense 5.4% of sales for full year (5.8% for Q4, 5.1% for FY 2012-13) ▪ New Integrated Product Development structure successfully implemented ▪ ~30% increase in efficiency and productivity levels ▪ Secured 3 year pipeline, >85% of 2014-15 critical laun
Slide 7: India (Rx and Gx)
India (Rx and Gx) India Significant increase in market share for Rs. crore branded generics – from 4.7% (6 months back) to 5.3%; continue to outpace market 17% 3,965 growth1 (16% vs 9% for industry) 3,396 17% growth in sales for the year India business contributed 40% to overall sales – compar
Slide 8: International
International International International business contributed 25% to Rs. crore overall sales (same share last year) 30% growth in sales for the year 30% 2,512 120+ countries, relationship with 180+ partners, range of 1000+ products 1,927 Completed Uganda integration (Key personnel CEO, CFO
Slide 9: South Africa
South Africa Cipla Medpro South Africa South Africa business contributed 13.5% to Rs. crore overall sales (on a consolidated basis) 26% growth in sales for the year – based 26% 774 on like for like sales New CEO on board (Paul Miller with 20+ 610 years pharmaceuticals experience); key personne
Slide 10: North America
North America North America North America business contributed 7% to Rs. crore overall sales – compared to 8% in FY 19% 740 2012-13 623 19% growth in sales for the year Expanded pipeline from 35 to >50 products – including several key respiratory products and other complex generics 16 filing
Slide 11: Europe and API
Europe Europe Europe business contributed 6% to overall Rs. crore sales – compared to 5.4% in FY 2012-13 40% 578 40% growth in sales for the year 410 Established lean front end presence in priority markets FY 12-13 FY 13-14 Focus on respiratory launches API API API contributed 7.5% to over
Slide 12: Priorities going forward
Priorities going forward 1. Clear Focus where we will play to win Further strengthen position in home markets (India & South Africa) Build front end in select key international markets 2. Successfully launch late stage pipeline Drive strong Focus on Europe respiratory launches sales + profit